Wadden, Thomas A.

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 5,205

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 4,058

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 2,735

2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Eckel, R. H., Jakicic, J. M., Ard, J. D., de Jesus, J. M., Miller, N. H., Hubbard, V. S., Lee, I.-M., Lichtenstein, A. H., Loria, C. M., Millen, B. E., et al. (2014) · Circulation

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 2,261

Mechanisms, Pathophysiology, and Management of Obesity

Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 1,867

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 1,828

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 1,444

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 1,419

2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk

Eckel, R. H., Jakicic, J. M., Ard, J. D., de Jesus, J. M., Houston Miller, N., Hubbard, V. S., Lee, I.-M., Lichtenstein, A. H., Loria, C. M., Millen, B. E., et al. (2014) · Journal of the American College of Cardiology

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 1,160

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 1,128

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 1,114

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 995

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 868

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance Randomized Study

on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 842

Systematic Review: An Evaluation of Major Commercial Weight Loss Programs in the United States

Tsai, A. G., & Wadden, T. A. (2005) · Annals of Internal Medicine

Pharmacology and Obesity TreatmentObesity, Physical Activity, Diet

Cited by 815

The science of obesity management: an endocrine society scientific statement

Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews

Pharmacology and Obesity TreatmentObesity, Physical Activity, Diet

Cited by 812

Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity

Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J. (2005) · New England Journal of Medicine

Pharmacology and Obesity TreatmentObesity, Physical Activity, Diet

Cited by 794

Primary Care Physicians’ Attitudes about Obesity and Its Treatment

Foster, G. D., Wadden, T. A., Makris, A. P., Davidson, D., Sanderson, R. S., Allison, D. B., & Kessler, A. (2003) · Obesity Research

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 744

Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial

Gregg, E. W., Jakicic, J. M., Blackburn, G. L., Bloomquist, P., Bray, G. A., Clark, J. M., Coday, M., Curtis, J. R., Egan, C., Evans, M., et al. (2016) · The Lancet Diabetes & Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 738

Lifestyle modification approaches for the treatment of obesity in adults.

Wadden, T. A., Tronieri, J. S., & Butryn, M. L. (2020) · American Psychologist

Obesity, Physical Activity, DietObesity and Health Practices

Cited by 661

Behavioral treatment of obesity

Butryn, M. L., Webb, V., & Wadden, T. A. (2011) · Psychiatric Clinics of North America

Obesity, Physical Activity, DietObesity and Health Practices

Cited by 636

Effects of Lifestyle Activity vs Structured Aerobic Exercise in Obese Women: A Randomized Trial

Andersen, R. E., Wadden, T. A., Bartlett, S. J., Zemel, B., Verde, T. J., & Franckowiak, S. C. (1999) · JAMA

Physical Activity and HealthObesity, Physical Activity, Diet

Cited by 623

Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes

Foster, G. D., Sanders, M. H., Millman, R., Zammit, G., Borradaile, K. E., Newman, A. B., Wadden, T. A., Kelley, D., Wing, R. R., Pi Sunyer, F. X., et al. (2009) · Diabetes Care

Obstructive Sleep Apnea ResearchSleep and related disorders

Cited by 600

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity

Obstructive Sleep Apnea ResearchPharmacology and Obesity Treatment

Cited by 583